SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:umu-209177"
 

Search: id:"swepub:oai:DiVA.org:umu-209177" > Single nucleotide p...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Oliva, DelmyDepartment of Oncology, Ryhov County Hospital, Jönköping, Sweden; delmy.oliva@rjl.se,Ryhov Cty Hosp, Sweden (author)

Single nucleotide polymorphism directed antiemetic treatment in women with breast cancer treated with neo- or adjuvant chemotherapy : a randomised multicentre phase II study. (EudraCT: 2015–000658-39)

  • Article/chapterEnglish2023

Publisher, publication year, extent ...

  • International Institute of Anticancer Research,2023
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:umu-209177
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-209177URI
  • https://doi.org/10.21873/anticanres.16433DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:hj:diva-60836URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-196093URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|Foundation for Clinical Cancer Research in Jonkoping and Futurum Academy for Health and Care, Region Jonkoping County; Medical Research Council of Southeast Sweden, FORSS
  • Background/aim: The role of single nucleotide polymorphisms (SNPs) in the frequency and intensity of chemotherapy-induced nausea and vomiting (CINV) in women with breast cancer (BC) is unclear. The primary purpose of this study was to compare/evaluate the effect of SNP-guided antiemetic treatment versus standard CINV treatment.Patients and methods: A randomised, factorial, phase II multicentre study design was used. Women planned for neoadjuvant or adjuvant chemotherapy with epirubicin, cyclophosphamide and fluorouracil (FEC /EC, with or without fluorouracil) for BC were randomised to SNP-guided antiemetic treatment (based on the results of SNP analyses) versus standard CINV treatment. Blood samples were taken before the treatment was initiated. Patient-reported data on CINV (during 10 days from onset of cancer treatment) and health-related quality of life (HRQoL), were collected before and after the first cancer treatment.Results: A total of 188 women were included. Overall, nausea was reported by 86% (n=129) of the patients during the ten-day period from the start of cancer treatment. The SNP genotype studied varied. In FAS-CD95, the genotypes AG and GG were overrepresented; in RB1-LPAR6, GG was overrepresented, and in CCL2, both AA and GG were overrepresented. We found no statistically significant difference in CINV between SNP-guided antiemetic treatment versus standard CINV treatment.Conclusion: SNP-guided antiemetic treatment could be as effective as standard treatment. SNP-guided antiemetic treatment of CINV is possibly useful in detecting patients with a higher or lower risk for CINV and thus may help in avoiding over-treatment with toxic components. CINV negatively affects the HRQL.Keywords: Breast cancer; chemotherapy-induced nausea and vomiting; single nucleotide polymorphism.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Andersson, Bengt-ÅkeJönköping University,HHJ, Avdelningen för naturvetenskap och biomedicin,HHJ. Biomedicinsk plattform,Jonkoping Univ, Sweden(Swepub:hj)andben (author)
  • Shamoun, LevarDepartment of Laboratory Medicine and Pathology, Region Jönköping County, Jönköping, Sweden,Reg Jonkoping Cty, Sweden (author)
  • Lewin, NongnitLinköpings universitet,Centrum för social och affektiv neurovetenskap,Medicinska fakulteten(Swepub:liu)nonle33 (author)
  • Nilsson, Mats P.Linköpings universitet,Institutionen för hälsa, medicin och vård,Medicinska fakulteten,Reg Jonkoping Cty, Sweden(Swepub:liu)n/a (author)
  • Schildt, Elsy-BrittDepartment of Oncology, Kalmar County Hospital, Kalmar, Sweden,Kalmar Cty Hosp, Sweden (author)
  • Fust, LisaDepartment of Oncology, Kalmar County Hospital, Kalmar, Sweden,Kalmar Cty Hosp, Sweden (author)
  • Åsenlund, UlrikaTrial Unit, Department of Oncology, Gävle County Hospital, Gävle, Sweden,Gavle Cty Hosp, Sweden (author)
  • Sellerstam, GunillaTrial Unit, Department of Oncology, SöderHospital AB, Stockholm, Sweden (author)
  • Elinder, EllinorTrial Unit, Department of Oncology, SöderHospital AB, Stockholm, Sweden (author)
  • Sharp, Lena,PhDUmeå universitet,Institutionen för omvårdnad,Department of Nursing, Umeå University, Umeå, Sweden; Regional Cancer Centre Stockholm-Gotland, Stockholm, Sweden,Umea Univ, Sweden; Reg Canc Ctr Stockholm Gotland, Sweden(Swepub:umu)lesh0006 (author)
  • Lewin, FreddiJönköping University,HHJ, Avdelningen för naturvetenskap och biomedicin,Department of Oncology, Ryhov County Hospital, Jönköping, Sweden,Ryhov Cty Hosp, Sweden; Jonkoping Univ, Sweden (author)
  • Department of Oncology, Ryhov County Hospital, Jönköping, Sweden; delmy.oliva@rjl.seRyhov Cty Hosp, Sweden (creator_code:org_t)

Related titles

  • In:Anticancer Research: International Institute of Anticancer Research43:6, s. 2671-26810250-70051791-7530

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view